Healthcare / BiotechnologyStockholm
$4.71
+0.02 (+0.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-19.8M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$100M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-74.6%
↓Gross Margin
98.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.4%
FCF CAGR
—
FCF margin
-252.0%
FCF / Net income
1.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.9M · net income $-12.2M · FCF $-17.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.9M | $6.9M | $4.7M | $5.5M | $5.0M |
| Net Income | $-12.2M | $-12.2M | $-15.1M | $-17.1M | $-13.8M |
| EBITDA | $-10.6M | $-10.6M | $-14.1M | $-16.3M | $-12.8M |
| EPS | -0.64 | -0.64 | -1.01 | -1.29 | -1.04 |
| Gross Margin | 98.4% | 98.4% | 100.7% | 60.9% | 58.7% |
| Operating Margin | -159.4% | -159.4% | -340.4% | -316.0% | -289.1% |
| Net Margin | -177.3% | -177.3% | -318.3% | -308.8% | -277.7% |
| Balance Sheet | |||||
| Current Ratio | 1.69 | 1.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-17.3M | $-17.3M | $-19.8M | $-32.7M | $3.0M |
| Returns | |||||
| ROE | -74.6% | -74.6% | -178.2% | -70.8% | -72.7% |
| Valuation | |||||
| P/B | 5.45 | 5.45 | 21.88 | 8.87 | 10.45 |
| Growth & Yield | |||||
| Revenue Growth | 44.7% | 44.7% | -14.4% | 11.5% | — |
| EPS Growth | 36.6% | 36.6% | 21.7% | -24.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+35.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.01 → -0.64
Residual
+35.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.